EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

5-Hydroxymethylcytosine profilings in circulating cell-free DNA as diagnostic biomarkers for DLBCL

Hangyu Chen, Maimaitiyasen Duolikun, Hai-Chuan Zhu

Frontiers in Cell and Developmental Biology · 15.11.2024 · 12

DOI: 10.3389/fcell.2024.1387959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 15.11.2024. Verfasst von Hangyu Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

5-Hydroxymethylcytosine (5hmC) is an important DNA epigenetic modification that plays a vital role in tumorigenesis, progression and prognosis. Previous studies have shown that it plays an important role in the prognosis of diffuse large B-cell lymphoma (DLBCL) and in the prediction of the efficacy of R-CHOP therapy. However, its potential for diagnosing DLBCL has not been reported. Here, we investigated the utility of 5hmC in plasma cfDNA in the diagnosis of DLBCL.

Methods

Applying 5hmC-Seal technique, we obtained genome-wide 5hmC profiles in plasma cell-free DNA (cfDNA) samples from 176 Chinese subjects, included 86 DLBCL patients and 90 healthy controls. To investigate whether 5hmC can be used as a diagnostic biomarker for DLBCL, we separated patients and healthy controls into training (DLBCL = 56, Healthy = 60) and validation (DLBCL = 30, Healthy = 30) cohorts and developed a 5hmC-based logistic regression model from the training cohort to diagnose the DLBCL patients in the validation cohort.

Results

In this study, we found 10 5hmC biomarkers, and the models created by these differentially regulated 5hmC modified genes showed high accuracy in distinguishing DLBCL patients from healthy controls (validation cohort: AUC = 0.94; (95% CI 88.8%–99.4%)).

Conclusion

Our study suggested that 5hmC markers derived from plasma cfDNA can served as effective epigenetic biomarkers for minimally invasive diagnosis of DLBCL.

Schlagwörter

Stichwörter der Autor:innen

5-hydroxymethylcytosine (5hmC)DLBCLcell-free DNAepigeneticslogistic regression modeling

Autor:innen und Institutionen

  • Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, China.
  • Department of Pharmacy, Peking University Third Hospital, Beijing, China.
  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou, China.

Zitieren

APA

Chen, H., Duolikun, M., & Zhu, H. C. (2024). 5-Hydroxymethylcytosine profilings in circulating cell-free DNA as diagnostic biomarkers for DLBCL. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1387959

Vancouver

Chen H, Duolikun M, Zhu HC. 5-Hydroxymethylcytosine profilings in circulating cell-free DNA as diagnostic biomarkers for DLBCL. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1387959

BibTeX
@article{Chen2024,
  author = {Chen, Hangyu and Duolikun, Maimaitiyasen and Zhu, Hai-Chuan},
  title = {5-Hydroxymethylcytosine profilings in circulating cell-free DNA as diagnostic biomarkers for DLBCL},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2024},
  volume = {12},
  doi = {10.3389/fcell.2024.1387959}
}
Kostenlos starten →